JAC Advance Access originally published online on September 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 616-622
© 2003 The British Society for Antimicrobial Chemotherapy
Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing
1 Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA; 3 Roger Williams Medical Center, Providence, RI; 4 Public Health Research Institute, Newark, NJ, USA; 2 Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow, 119021 Russia
Received 13 March 2003; returned 12 May 2003; revised 1 July 2003; accepted 6 July 2003
Objectives: According to the mutant selection window (MSW) hypothesis, resistant mutants are selected or enriched at antibiotic concentrations above the MIC but below the mutant prevention concentration (MPC). To test this hypothesis, Streptococcus pneumoniae ATCC 49619 (MIC 0.1 mg/L; MPC 0.5 mg/L) was exposed to moxifloxacin concentrations below the MIC, above the MPC and between the MIC and MPC, i.e. within the MSW.
Methods: Daily administration of moxifloxacin for 3 consecutive days was mimicked using a two-compartment dynamic model with peripheral units containing a starting inoculum of 108 cfu/mL S. pneumoniae. Changes in susceptibility were examined by repeated MIC determinations and by plating the specimens on agar containing zero, 2 x MIC, 4 x MIC and 8 x MIC of moxifloxacin.
Results: Both in terms of the MIC and resistance frequency, S. pneumoniae resistance developed at concentrations that fell inside the MSW [ratios of 24 h area under the curve (AUC24) to MIC between 24 and 47 h]. A Gaussian-like function fitted the AUC24/MIC-dependent increases in MIC and resistance frequency with central points at AUC24/MICs of 38 and 42 h, respectively, where resistant mutants are enriched selectively. Selective enrichment of resistant mutants was not seen at AUC24/MICs <10 h or >100 h.
Conclusions: These data suggest that AUC24/MICs >100 h may protect against the selection of resistant S. pneumoniae mutants. Since the usual 400 mg dose of moxifloxacin provides much higher AUC24/MIC (270 h), it is expected to prevent mutant selection at clinically achievable concentrations. Also, these data provide further support for the MSW hypothesis.
* Corresponding author. Tel: +7-095-245-0154; Fax: +7-095-245-0295; E-mail: firsov{at}dol.ru
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. V. Smirnova, S. N. Vostrov, E. V. Strukova, S. A. Dovzhenko, M. B. Kobrin, Y. A. Portnoy, S. H. Zinner, and A. A. Firsov The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models J. Antimicrob. Chemother., October 1, 2009; 64(4): 815 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Allen and C. D. Hankins Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae J. Antimicrob. Chemother., August 1, 2009; 64(2): 359 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ferran, A.-S. Kesteman, P.-L. Toutain, and A. Bousquet-Melou Pharmacokinetic/Pharmacodynamic Analysis of the Influence of Inoculum Size on the Selection of Resistance in Escherichia coli by a Quinolone in a Mouse Thigh Bacterial Infection Model Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3384 - 3390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Firsov, I. Y. Lubenko, M. V. Smirnova, E. N. Strukova, and S. H. Zinner Enrichment of Fluoroquinolone-Resistant Staphylococcus aureus: Oscillating Ciprofloxacin Concentrations Simulated at the Upper and Lower Portions of the Mutant Selection Window Antimicrob. Agents Chemother., June 1, 2008; 52(6): 1924 - 1928. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Zinner, D. Gilbert, I. Yu. Lubenko, K. Greer, and A. A. Firsov Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline J. Antimicrob. Chemother., March 1, 2008; 61(3): 629 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Homma, T. Hori, G. Sugimori, and Y. Yamano Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3810 - 3815. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferran, V. Dupouy, P.-L. Toutain, and A. Bousquet-Melou Influence of Inoculum Size on the Selection of Resistant Mutants of Escherichia coli in Relation to Mutant Prevention Concentrations of Marbofloxacin Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4163 - 4166. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Olofsson, L. L. Marcusson, A. Stromback, D. Hughes, and O. Cars Dose-related selection of fluoroquinolone-resistant Escherichia coli J. Antimicrob. Chemother., October 1, 2007; 60(4): 795 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. T. Stearne, W. H. F. Goessens, J. W. Mouton, and I. C. Gyssens Effect of Dosing and Dosing Frequency on the Efficacy of Ceftizoxime and the Emergence of Ceftizoxime Resistance during the Early Development of Murine Abscesses Caused by Bacteroides fragilis and Enterobacter cloacae Mixed Infection Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3605 - 3611. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Firsov, M. V. Smirnova, I. Yu. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model J. Antimicrob. Chemother., December 1, 2006; 58(6): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Olofsson, L. L. Marcusson, P. Komp Lindgren, D. Hughes, and O. Cars Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration J. Antimicrob. Chemother., June 1, 2006; 57(6): 1116 - 1121. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Marcusson, S. K. Olofsson, P. K. Lindgren, O. Cars, and D. Hughes Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli J. Antimicrob. Chemother., June 1, 2005; 55(6): 938 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J Epstein, J. G Gums, and K. Drlica The Changing Face of Antibiotic Prescribing: The Mutant Selection Window Ann. Pharmacother., October 1, 2004; 38(10): 1675 - 1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Croisier, M. Etienne, L. Piroth, E. Bergoin, C. Lequeu, H. Portier, and P. Chavanet In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants J. Antimicrob. Chemother., September 1, 2004; 54(3): 640 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Linde and N. Lehn Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions J. Antimicrob. Chemother., February 1, 2004; 53(2): 252 - 257. [Abstract] [Full Text] [PDF] |
||||


